Sign In
Buy VIVO
$3.90
+0.170 (+4.56%)
At Close: Aug 04, 2026
Meridian Bioscience receives NIH Award for supporting rapid development of Revogene® molecular test for SARS-CoV-2
03:00pm, Wednesday, 16'th Dec 2020
CINCINNATI, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it has been awar
Meridian Bioscience submits application to FDA for Emergency Use Authorization for SARS-CoV-2 molecular assay
10:17am, Tuesday, 08'th Dec 2020
CINCINNATI, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it has submitted
CINCINNATI, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that i
Meridian Bioscience Participates in Piper Sandler 32nd Annual Virtual Healthcare Conference
10:00am, Monday, 23'rd Nov 2020
CINCINNATI, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference. Jack Kenny, Chi
Has Meridian Bioscience (VIVO) Outpaced Other Medical Stocks This Year?
11:30am, Tuesday, 17'th Nov 2020
Is (VIVO) Outperforming Other Medical Stocks This Year?
Meridian Bioscience to Participate in Canaccord Genuity Virtual MedTech & Diagnostics Forum
12:00pm, Monday, 16'th Nov 2020
CINCINNATI, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today that Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief
Meridian Bioscience's (VIVO) CEO Jack Kenny on Q4 2020 Results - Earnings Call Transcript
01:52pm, Friday, 13'th Nov 2020
Meridian Bioscience's (VIVO) CEO Jack Kenny on Q4 2020 Results - Earnings Call Transcript
